Total Funding
32
61
Total FundingPost-IPO Equity raised
Growth Score
2 pts
Heat Score
-27 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
71951
Theravance Biopharma is a biopharmaceutical company with one approved product.
George Whitesides: Co-FounderPast Role: Massachusetts Institute of Technology, Faculty Member
Christopher Porter: Vice President, Development Strategy and InnovationPast Role: Clinipace, Clinipace Worldwide
About the Company
Theravance Biopharma is a biopharmaceutical company with one approved product, VIBATIV® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. In addition, they have an economic interest in future payments that may be made by
GlaxoSmithKline plc (GSK) pursuant to its agreements with Theravance, Inc. relating to certain drug programs, including the combination of umeclidinium (UMEC), vilanterol (VI) and fluticasone furoate (FF) (UMEC/VI/FF), the combination of the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) GSK961081 (‘081) and FF (‘081/FF), and MABA monotherapy.
